Product Description
OK-201 is a lipidated cyclized bovine adrenal medulla (“BAM8”) analogue, a promising candidate for the treatment of neuropathic and inflammatory pain. (Sourced from: https://www.okyopharma.com/okyo-pharma-announces-positive-data-and-results-in-an-animal-model-using-topically-administered-ok-201-to-treat-neuropathic-ocular-pain/)
Mechanisms of Action: MRGPRX1 Activator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Ocular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OKYO Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Corneal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|